Novartis signs $2B acquisition to expand food-allergy drug pipeline
Synopsis
Novartis has signed a deal to acquire US-based biotechnology company Excellergy for up to $2 billion. The acquisition is aimed at strengthening the company’s pipeline in food-allergy treatments. The deal is expected to close in the second half of 2026, subject to regulatory approvals and other standard conditions.
Novartis has agreed to acquire US biotechnology firm Excellergy in a deal worth up to $2 billion. The acquisition focuses on food-allergy treatments and reflects growing global demand, including in markets such as Australia where allergy rates continue to rise.
Key Highlights
- Novartis to acquire US biotech firm Excellergy in a deal worth up to $2 billion.
- The acquisition focuses on treatments for food allergies, a fast-growing healthcare segment.
- The transaction includes upfront and milestone-based payments linked to drug development.
- The deal is expected to close in the second half of 2026 after regulatory approvals.
Novartis has agreed to acquire US biotechnology company Excellergy in a deal valued at up to $2 billion, as the Swiss drugmaker increases investment in new allergy treatments.
The agreement includes upfront payments along with milestone-based payments tied to the development of new medicines.
The transaction is expected to close in the second half of 2026, subject to regulatory approvals.
It follows another recently announced biotech acquisition worth up to $3 billion, showing a broader push by the company to strengthen its future drug pipeline.
A US biotech startup focused on allergy treatments
Excellergy is a United States-based biotechnology company focused on developing treatments for food allergy patients.
The company has been working on a new drug candidate designed to help patients manage allergic reactions more effectively, especially in cases where existing treatments are limited.
The firm was founded by researchers and drug-development specialists with experience in immunology and allergy-related medicines.
Like many early-stage biotech companies in the US, it has focused primarily on clinical research rather than commercial products so far.
Why the deal matters to the Australian market
The acquisition has direct relevance for Australia because the country reports some of the highest food-allergy rates globally, particularly among children.
Medical research published in international journals has repeatedly identified Australia as one of the leading regions in allergy-related research and diagnosis.
Healthcare spending on allergic diseases has also increased steadily in Australia over the past decade. As a result, new treatments in this segment often reach the Australian market relatively quickly once approved in major regions such as the United States and Europe.
Growing importance of the allergy-treatment sector
Large pharmaceutical companies have been increasing investment in immunology and allergy treatments as demand rises globally.
This includes medicines for asthma, food allergies and immune-related conditions.
Novartis already has a presence in this segment through its existing allergy-related medicines, and the Excellergy acquisition is expected to strengthen its position in future treatments.
FAQs
Q1. What is the value of the Novartis–Excellergy deal?
The acquisition is valued at up to $2 billion, including milestone-based payments tied to drug development.
Q2. What does Excellergy do?
Excellergy is a US biotechnology company developing treatments for food-allergy patients.
Q3. When will the deal close?
The transaction is expected to close in the second half of 2026, subject to regulatory approvals.
Q4. Why is Novartis investing in allergy treatments?
Demand for food-allergy and immunology medicines is rising globally, especially in developed healthcare markets.
Follow Inspirepreneur Magazine for the business news.
Pooja Malik is a business journalist with over six years of experience covering startups, entrepreneurship, and emerging trends. She has previously worked with leading media platforms such as YourStory Media and BW BusinessWorld, where she reported on business, policy, and market developments. Currently, she serves as Editor at The Inspirepreneur Magazine, where she writes and edits stories across business, lifestyle, and travel, with a focus on clarity, accuracy, and reader relevance.
